HC Wainwright Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics (NASDAQ:PVLA) had its target price hoisted by analysts at HC Wainwright from $255.00 to $270.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 124.27% from the stock’s previous close.

A number of other research firms also recently issued reports on PVLA. UBS Group restated a “buy” rating and issued a $143.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. BTIG Research lifted their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Oppenheimer restated an “outperform” rating and set a $200.00 target price on shares of Palvella Therapeutics in a research note on Monday, December 15th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $193.00 target price on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Finally, Truist Financial set a $210.00 price target on Palvella Therapeutics in a report on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $195.93.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $120.39 on Tuesday. Palvella Therapeutics has a fifty-two week low of $18.23 and a fifty-two week high of $151.18. The business has a 50-day simple moving average of $103.99 and a two-hundred day simple moving average of $89.76. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -45.78 and a beta of -0.30.

Insider Buying and Selling

In related news, Director George M. Jenkins bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the purchase, the director owned 187,171 shares of the company’s stock, valued at approximately $23,396,375. The trade was a 2.18% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Elaine J. Heron purchased 2,400 shares of Palvella Therapeutics stock in a transaction on Friday, February 27th. The stock was bought at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the acquisition, the director owned 47,812 shares in the company, valued at $5,976,500. The trade was a 5.28% increase in their position. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Several large investors have recently made changes to their positions in PVLA. First Light Asset Management LLC purchased a new stake in shares of Palvella Therapeutics in the third quarter worth about $33,949,000. Summit Partners Public Asset Management LLC boosted its stake in Palvella Therapeutics by 1,016.0% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock valued at $40,761,000 after buying an additional 354,525 shares during the last quarter. Federated Hermes Inc. purchased a new position in Palvella Therapeutics during the 3rd quarter valued at approximately $21,255,000. Vanguard Group Inc. grew its holdings in Palvella Therapeutics by 202.0% during the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after buying an additional 330,847 shares in the last quarter. Finally, State Street Corp increased its stake in Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock worth $44,010,000 after acquiring an additional 283,211 shares during the last quarter. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.